VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHOC 2022 | The importance of analyzing cytogenetic risk in patients with AML undergoing haploidentical SCT

In this video, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the importance of analyzing cytogenetic risk in patients with acute myeloid leukemia (AML) undergoing haploidentical stem cell transplantation (SCT). Prof. Nagler first gives an overview of the biology behind haploidentical SCT, and then goes on to explain the role of cytogenetics as an important prognostic factor in patients undergoing transplantation. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter